Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

CEO Stéphane Bancel said the vaccine maker aims to reduce 2025 cash costs by $1 billion with a plan for an additional $500 million in 2026. It expects to end 2025 with cash and investments of about $6 ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

It was a Chinese media outlet that reported that Chief Executive Stéphane Bancel was visiting Shanghai to sign a pact with local authorities for Moderna to research, develop and manufacture ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

CEO Stéphane Bancel emphasised saving cash as integral in the company’s bid to parlay Covid-19 profits into future profitability.

Only 23 countries use climate data for health surveillance, says head of WMO, adding more collaboration needed ...